ALNYLAM PHARMACEUTICALS, INC. 8-K

What Happened

• Alnylam Pharmaceuticals, Inc. announced its financial results for the quarter ended December 31, 2025. The company filed a Current Report on Form 8-K on February 12, 2026 to disclose the announcement.
• The full text of the press release containing the results was furnished with the 8-K as Exhibit 99.1. The 8-K reports Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits).

Key Details

• Filing date: February 12, 2026 (Form 8-K).
• Reporting period: quarter ended December 31, 2025.
• Press release with the detailed results is furnished as Exhibit 99.1 to the 8-K.
• Items disclosed on the 8-K: 2.02 (results of operations and financial condition) and 9.01 (exhibits).

Why It Matters

• This 8-K announces Alnylam’s latest quarterly earnings information — key data investors use to evaluate revenue, profits, and near-term performance.
• The furnished press release will include the specific figures (revenue, net income/loss, guidance if provided) that can affect the stock price and investor decisions; investors should read Exhibit 99.1 and any accompanying SEC filings for the full financial details.